The sympathetic branch of the Autonomic nervous system originates in the thoracolumbar spinal cord (T1-L2) and mobilizes organismal resources during stress, threat, or activity through the release of catecholamines (norepinephrine from nerve terminals, Adrenaline from the adrenal Medulla). This system orchestrates a coordinated cascade involving cardiovascular activation, metabolic switching toward Glucose mobilization, immune redistribution, and visceral suppression, mediated primarily through alpha- and β2-adrenergic receptors on target tissues.
Think of the sympathetic nervous system as your body's emergency broadcasting network—like the sirens that alert a city when a tornado is approaching. When the alarm sounds, every department receives the same urgent message: "Drop non-essential activities and redirect all resources to survival." The fire station (heart) cranks up its pumps and narrows the hoses (vasoconstriction) to increase water pressure. The power plant (liver) stops storing fuel and floods the grid with emergency Glucose. The sanitation department (gut) shuts down—no time for digesting lunch when a tornado is overhead. Even the immune patrol cars (leukocytes) abandon their regular neighbourhood beats and rush to the bloodstream highways, ready for injury. Meanwhile, the body's water supply becomes thick and concentrated (saliva becomes viscous, high in Amylase), and the mouth's protective barrier (salivary IgA) drops because the city can't afford to maintain peacetime defences during an emergency. This is perfect—for 10 minutes. But if the siren never stops (chronic sympathetic dominance), the fire station burns out, the power plant runs dry, sanitation fails, and the patrol cars crash from exhaustion. The city begins to crumble under constant alert.
Sympathetic preganglionic neurons originate in the intermediolateral cell column (IML) of the thoracolumbar spinal cord (T1-L2). These short preganglionic fibers synapse in paravertebral (sympathetic chain) or prevertebral ganglia, releasing Acetylcholine onto nicotinic receptors. Long postganglionic neurons then project to target organs, releasing norepinephrine (NE) at nerve terminals. The adrenal medulla, a modified sympathetic ganglion, releases 80% Adrenaline and 20% norepinephrine directly into circulation.
¶ Neurotransmitter Release and Receptor Activation
graph TD
A[Preganglionic neuron T1-L2] -->|ACh nicotinic| B[Postganglionic neuron in ganglion]
B -->|Norepinephrine| C["Target organ α/β-adrenergic receptors"]
A -->|ACh nicotinic| D[Adrenal medulla chromaffin cells]
D -->|80% Adrenaline 20% NE| E[Systemic circulation]
C --> F["α1: vasoconstriction smooth muscle contraction"]
C --> G["α2: presynaptic NE inhibition central effects"]
C --> H["β1: heart rate contractility renin release"]
C --> I["β2: bronchodilation vasodilation metabolic effects"]
E --> I
- β1-adrenergic activation in cardiac myocytes → increased cAMP → PKA activation → phosphorylation of L-type Ca²⁺ channels and phospholamban → increased Ca²⁺ influx and sarcoplasmic reticulum release → increased heart rate (positive chronotropy), contractility (positive inotropy), and conduction velocity
- α1-adrenergic activation in vascular smooth muscle → Gq-protein coupling → phospholipase C → IP₃ and DAG → Ca²⁺ release → myosin light chain kinase activation → vasoconstriction → increased blood pressure
- Renal β1 activation → juxtaglomerular cells release renin → angiotensinogen → angiotensin I → ACE → Ang II → aldosterone (RAA system activation)
- Hepatic effects: β2-receptors → cAMP/PKA → phosphorylation of hormone-sensitive lipase (HSL) and glycogen phosphorylase → glycogenolysis and lipolysis → plasma Glucose and free fatty acids elevation
- Adipocyte effects: β-adrenergic activation → HSL phosphorylation → triglyceride breakdown → fatty acid oxidation → ketogenesis substrate provision
- Pancreatic suppression: α2-receptors on beta cells → inhibition of insulin release → permissive environment for Glucose elevation (synergy with counter-regulatory cortisol)
- Net result: shift from anabolic (storage) to catabolic (mobilization) metabolism; insulin resistance at skeletal muscle to preserve Glucose for brain and immune cells (selfish brain)
- β2-adrenergic receptor on leukocytes → cAMP elevation → PKA activation → dual effects:
- Acute (minutes): leukocyte demargination from vessel walls → catecholamine-induced leukocytosis (redistribution from marginated pool to circulation)
- Subacute (hours): modulation of cytokine production via CREB and NF-kB pathways
- Norepinephrine binding to β2 on monocytes/macrophages → shift toward pro-inflammatory phenotype in some contexts (increased IL-6, TNF-α) but anti-inflammatory in others (increased IL-10) depending on timing and tissue context
- Splenic nerve activation → NE release in white pulp → T cells and B cells receptor engagement → altered trafficking and antibody production
- Thymic involution accelerated by chronic sympathetic tone → reduced naïve T cell output
Sympathetic activation produces characteristic saliva composition shifts detectable clinically:
- Amylase elevation: sympathetic nerves innervating parotid and submandibular glands → β-adrenergic stimulation → acinar cell secretion of α-amylase (stress biomarker; levels >200 U/mL indicate high sympathetic tone)
- Water reduction: vasoconstriction reduces plasma filtration into glands → viscous, thick saliva
- pH reduction: shift from bicarbonate-rich (parasympathetic) to acidic saliva (pH <6.8 indicates sympathetic dominance)
- salivary IgA (sIgA) suppression: reduced parasympathetic drive and local cortisol effects → decreased plasma cell IgA production and transcytosis → compromised mucosal immunity
- Monosaccharide elevation: altered glycoprotein processing and secretion
- Rostral ventrolateral medulla (RVLM): primary sympathetic pre-motor neurons; integrates input from:
- Paraventricular nucleus (PVN) of hypothalamus → CRH and vasopressin neurons → descending excitation
- Amygdala (threat processing) → bed nucleus of stria terminalis → PVN/RVLM
- Nucleus tractus solitarius (NTS) → baroreceptor and chemoreceptor feedback
- Inhibitory modulation: nucleus ambiguus and dorsal motor nucleus of vagus provide reciprocal parasympathetic tone; GABAergic neurons in caudal ventrolateral medulla (CVLM) inhibit RVLM
Chronic sympathetic overactivation is a core pathophysiological driver in modern Non-Communicable Diseases, reflecting evolutionary mismatch between ancestral intermittent stressors and contemporary chronic psychosocial stress.
Cardiovascular: Persistent vasoconstriction and RAA-system activation → hypertension, atherosclerosis, heart failure. Elevated resting heart rate (>80 bpm) and reduced heart rate variability (HRV <50 ms SDNN) indicate autonomic imbalance. Clonidine (α2-agonist) reduces central sympathetic outflow therapeutically.
Metabolic: sympathetic tone elevates counter-regulatory hormones (cortisol, norepinephrine, Adrenaline) → insulin resistance, hyperglycaemia, visceral fat accumulation → metabolic syndrome. The selfish brain prioritizes cerebral Glucose under chronic stress, sacrificing peripheral insulin sensitivity.
Immune: Chronic catecholamine exposure → inflammation (elevated IL-6, TNF-α, CRP >3 mg/L), immune exhaustion, and cytokine resistance. Reduced sIgA compromises oral barrier and gut barrier integrity → dysbiosis, endotoxaemia, systemic inflammation.
Pain: Sympathetic activation sensitizes TRPV1 and TRPA1 channels on nociceptors → central sensitization, allodynia. Chronic pain syndromes (Fibromyalgia, chronic pain) show elevated sympathetic markers and reduced parasympathetic buffering.
Reproductive: Chronic stress → hypothalamic inflammation → GnRH suppression → Infertility, menstrual irregularities, Testosterone reduction in males.
- Salivary biomarkers: Amylase (>200 U/mL = high stress), pH (<6.8 = dominance), sIgA (<25 mg/dL = barrier compromise), water content (viscosity assessment)
- Heart rate variability: time-domain (SDNN, RMSSD) and frequency-domain (LF/HF ratio >2.5 suggests sympathetic dominance)
- Blood markers: resting norepinephrine (>400 pg/mL), Adrenaline, cortisol (flattened diurnal curve with elevated evening levels >5 μg/dL)
- Inflammatory: CRP, IL-6, TNF-α, neutrophil-lymphocyte ratio (>3 indicates stress-immune axis activation)
Metamodel 0 (Evolutionary Context): Recognize chronic psychosocial stress as mismatch; reintroduce Intermittent Living patterns (fasting, cold exposure, physical variability).
Metamodel 1 (Barriers): Restore salivary IgA and gut barrier via parasympathetic activation (breathwork, chewing, vagus nerve stimulation).
Metamodel 3 (Immunology): Address inflammation via resolution pathways (omega-3 fatty acids, SPMs), reduce catecholamine-driven immune activation.
Metamodel 5 (Neuroendocrine): HPA axis recalibration via circadian restoration (melatonin, light therapy), adaptogenic herbs (Ashwagandha, Rhodiola rosea), and stress reappraisal (cognitive interventions).
Direct autonomic interventions: Breathwork (4-7-8 pattern, coherent breathing at 6 breaths/min), vagus nerve stimulation (cold face immersion, gargling, singing), Heart rate variability biofeedback, Meditation, Tai Chi Chih.
The sympathetic system exemplifies the selfish brain and selfish immune system concepts: under chronic stress, the brain monopolizes Glucose (perpetuating insulin resistance) while the immune system shifts resources toward inflammatory vigilance at the expense of resolution and tolerance. This zero-sum resource allocation drives multi-system pathology.
- Sympathetic preganglionic neurons originate in intermediolateral column T1-L2; postganglionic neurons release norepinephrine at targets
- Adrenal medulla releases 80% Adrenaline, 20% norepinephrine upon sympathetic stimulation
- Salivary markers of sympathetic activation: Amylase >200 U/mL, pH <6.8, sIgA <25 mg/dL, reduced water (viscous saliva), elevated monosaccharides
- β2-adrenergic receptor on leukocytes mediates catecholamine-induced leukocytosis (demargination) and cytokine modulation
- Chronic sympathetic tone suppresses insulin secretion (α2-pancreatic) and induces peripheral insulin resistance (β-adrenergic counter-regulation)
- Clonidine (α2-agonist) reduces central sympathetic outflow; clinically used in hypertension, ADHD, opioid withdrawal
- Resting heart rate >80 bpm and heart rate variability <50 ms SDNN indicate sympathetic dominance
- CRP >3 mg/L, IL-6 >10 pg/mL, neutrophil-lymphocyte ratio >3 reflect chronic sympathetic-immune activation
- Sympathetic-driven RAA-system activation: β1-renal → renin → Ang II → aldosterone → sodium retention, vasoconstriction, hypertension
- Cortisol peaks physiologically at 06:00-08:00; flattened curve with evening elevation >5 μg/dL indicates HPA axis dysregulation linked to sympathetic dominance
- parasympathetic — reciprocal branch of Autonomic nervous system; parasympathetic rest-and-digest opposes sympathetic mobilization; autonomic balance requires coordinated oscillation between branches
- sympathetic dominance — chronic overactivation state producing multi-system pathology including inflammation, insulin resistance, immune suppression, and pain sensitization
- HPA axis — works synergistically with sympathetic system during acute stress response; CRH from PVN activates both ACTH-cortisol cascade and descending sympathetic pathways
- cortisol — released via HPA axis during sympathetic activation; synergistic metabolic effects (gluconeogenesis, lipolysis); chronic elevation drives cortisol resistance
- norepinephrine — primary neurotransmitter of postganglionic sympathetic neurons; binds α and β receptors on cardiovascular, metabolic, and immune targets
- Adrenaline — released from adrenal medulla (80% of catecholamine output); systemic effects via β-receptors including bronchodilation, metabolic activation, immune modulation
- amylase — salivary enzyme dramatically elevated (>200 U/mL) during sympathetic activation; clinical biomarker of stress exposure
- sIgA — suppressed by chronic sympathetic tone via reduced parasympathetic drive and local cortisol; compromises oral barrier and gut barrier mucosal immunity
- inflammation — driven by sympathetic activation through β2-adrenergic receptor on leukocytes → IL-6, TNF-α, CRP elevation; chronic pattern in sympathetic dominance
- insulin resistance — promoted by sympathetic counter-regulatory effects: α2-pancreatic suppression of insulin, β-adrenergic lipolysis → free fatty acids, cortisol synergy
- vagus nerve — primary parasympathetic pathway; vagal tone inversely related to sympathetic activity; Heart rate variability reflects vagal-sympathetic balance
- Autonomic nervous system — sympathetic comprises mobilization/stress branch opposing parasympathetic conservation/restoration branch
- fight-or-flight response — acute sympathetic activation pattern producing cardiovascular, metabolic, and immune mobilization for threat response
- heart rate variability — reduced by sympathetic dominance; HRV <50 ms SDNN indicates autonomic imbalance and cardiovascular risk
- blood pressure — elevated by sympathetic vasoconstriction (α1) and increased cardiac output (β1); chronic elevation → hypertension, CVD
- chronic stress — produces sustained sympathetic activation → sympathetic dominance, allostatic load, multi-system disease
- β2-adrenergic receptor — G-protein coupled receptor on leukocytes, hepatocytes, adipocytes, bronchial smooth muscle; mediates immunomodulation, lipolysis, glycogenolysis, bronchodilation
- clonidine — α2-adrenergic agonist reducing central sympathetic outflow via presynaptic negative feedback; used therapeutically in hypertension, ADHD, opioid withdrawal
- CRP — acute phase protein elevated (>3 mg/L) with chronic sympathetic-immune activation; biomarker of Low-Grade Inflammation
- metabolic syndrome — cluster of insulin resistance, hypertension, dyslipidemia, visceral adiposity driven by chronic sympathetic dominance and HPA axis dysregulation
- breathwork — intervention to reduce sympathetic tone via vagal afferent activation; coherent breathing (6 breaths/min) increases Heart rate variability and parasympathetic balance
- RAA-system — renin-angiotensin-aldosterone cascade activated by sympathetic β1-renal stimulation; drives sodium retention, vasoconstriction, volume expansion
- IL-6 — pro-inflammatory cytokine elevated (>10 pg/mL) by chronic sympathetic-immune interaction; drives acute phase response, CRP production, insulin resistance
- TNF-α — pro-inflammatory cytokine modulated by β-adrenergic signaling on macrophages; elevated in sympathetic dominance contributing to metabolic dysfunction
- stress — primary trigger of sympathetic activation; chronic psychosocial stress reflects evolutionary mismatch producing pathological sympathetic dominance
- selfish brain — concept explaining sympathetic-driven insulin resistance: brain prioritizes cerebral Glucose supply under stress at expense of peripheral tissues
- Glucose — mobilized via sympathetic-driven glycogenolysis (liver) and gluconeogenesis; plasma elevation via insulin suppression and counter-regulatory hormone synergy
- Module 1 — Autonomic nervous system architecture, stress physiology, saliva testing interpretation
- Module 5 — Neuroendocrine integration, HPA axis interaction, hypothalamus control of sympathetic outflow